eLife (Nov 2020)

Reprogramming of bone marrow myeloid progenitor cells in patients with severe coronary artery disease

  • Marlies P Noz,
  • Siroon Bekkering,
  • Laszlo Groh,
  • Tim MJ Nielen,
  • Evert JP Lamfers,
  • Andreas Schlitzer,
  • Saloua El Messaoudi,
  • Niels van Royen,
  • Erik HJPG Huys,
  • Frank WMB Preijers,
  • Esther MM Smeets,
  • Erik HJG Aarntzen,
  • Bowen Zhang,
  • Yang Li,
  • Manita EJ Bremmers,
  • Walter JFM van der Velden,
  • Harry Dolstra,
  • Leo AB Joosten,
  • Marc E Gomes,
  • Mihai G Netea,
  • Niels P Riksen

DOI
https://doi.org/10.7554/eLife.60939
Journal volume & issue
Vol. 9

Abstract

Read online

Atherosclerosis is the major cause of cardiovascular disease (CVD). Monocyte-derived macrophages are the most abundant immune cells in atherosclerotic plaques. In patients with atherosclerotic CVD, leukocytes have a hyperinflammatory phenotype. We hypothesize that immune cell reprogramming in these patients occurs at the level of myeloid progenitors. We included 13 patients with coronary artery disease due to severe atherosclerosis and 13 subjects without atherosclerosis in an exploratory study. Cytokine production capacity after ex vivo stimulation of peripheral blood mononuclear cells (MNCs) and bone marrow MNCs was higher in patients with atherosclerosis. In BM-MNCs this was associated with increased glycolysis and oxidative phosphorylation. The BM composition was skewed towards myelopoiesis and transcriptome analysis of HSC/GMP cell populations revealed enrichment of neutrophil- and monocyte-related pathways. These results show that in patients with atherosclerosis, activation of innate immune cells occurs at the level of myeloid progenitors, which adds exciting opportunities for novel treatment strategies.

Keywords